IMUC ImmunoCellular Therapeutics, Ltd. gains 33% Jul 10, 2017

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing other therapeutic DC vaccines, such as ICT-140 for ovarian cancer; and ICT-121 to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California. http://www.priceseries.com/trade/IMUC-ImmunoCellular-Therapeutics-Ltd-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2017070320170710.html